Electra Therapeutics, Inc. (ETRA)
| Market Cap | 472.01M |
| Revenue (ttm) | n/a |
| Net Income | -95.20M |
| EPS | -2,163.66 |
| Shares Out | 62.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,651 |
| Open | 8.07 |
| Previous Close | 8.07 |
| Day's Range | 6.87 - 8.25 |
| 52-Week Range | 6.90 - 15.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 33.20 (+341.49%) |
| Est. Earnings | Nov 22, 2026 |
About ETRA
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete ac... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ETRA stock is "Strong Buy." The 12-month stock price target is $33.2, which is an increase of 341.49% from the latest price.
News
Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision ...
Electra Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Electra Therapeutics (ETRA) with a Buy rating and $30 price target Electra is a late clinical-stage biopharmaceutical company focused o...
Electra Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama initiated coverage of Electra Therapeutics (ETRA) with an Overweight rating and $36 price target The firm says the company’s ipsoprubart, currently in a Phase 2/3 pivotal…
Electra Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Electra Therapeutics (ETRA) with an Overweight rating. Electra is pioneering a novel immunology approach with ipsoprubart, a pan-SIRP-targeting immune cell depl...
Electra Therapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of Electra Therapeutics (ETRA) with a Buy rating and $32 price target Electra is a clinical-stage biotech developing SIRP-directed therapies, with lead asset ipsoprubart b...
Electra Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Electra Therapeutics (ETRA) with an Overweight rating.
Electra Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Electra Therapeutics (ETRA) with an Outperform rating and $36 price target Lead asset ipsoprubart showed a 100% eight-week survival signal in a disease where the…
Electra Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Electra Therapeutics (ETRA) with a Buy rating and no price target The firm believes ipsoprubart has the potential to transform secondary hemophagocytic lymphohistiocytos...
Opening Day: Electra Therapeutics, Orion180 make market debuts
Nscale Limited has filed for an IPO and aims to list on the New York Stock Exchange, as Electra Therapeutics and Orion180 Insurance made their market debuts after pricing their…
Kinzey Capital Management: Electra Sets Nasdaq IPO Terms
Kinzey Capital Management, based in Singapore, runs discretionary multi-asset portfolios serving private clients, corporates, families and foundations.
Electra Therapeutics opens at $15, IPO priced at $15 per share
Electra Therapeutics (ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, priced i...
Electra Therapeutics indicated to open at $20, IPO priced at $15
Electra Therapeutics (ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, priced i...
Electra Therapeutics indicated to open at $16.25, IPO priced at $15
10:54 EDT Electra Therapeutics (ETRA) indicated to open at $16.25, IPO priced at $15
Electra Therapeutics 23.33M share IPO priced at $15.00
Jefferies, TD Cowen, Evercore ISI and Cantor Fitzgerald are acting as joint book running managers for the offering. The deal size was increased to 23.3M shares of common stock from…
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for...
Electra Therapeutics Registration statement: Registration filing
Electra Therapeutics filed a registration statement on September 14, 2026, providing details about a securities offering with the SEC.
Electra Therapeutics targets $977.6 million valuation in US IPO
Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its U.S. initial public offering, according to a filing on Monday, extending a comeback in biotech listings th...
Electra Therapeutics IPO Registration Document (S-1)
Electra Therapeutics has filed to go public with an IPO on the NASDAQ
Antibody biotech Electra Therapeutics files for a $100 million IPO
Electra Therapeutics, a late clinical-stage biotech developing antibodies targeting signal regulatory proteins for immune-mediated diseases and cancer, filed on Friday with the SEC to raise up to $100...